title: In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
abstract: We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44%), ciprofloxacin (75%), amikacin (69%), sulbactam (34%) and all four antibiotics (22%), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71% to 82%. The minimum inhibitory concentration (MIC) of tigecycline ranged from 0.6 to 16 microg/mL (MIC(50) 2 microg/mL; MIC(90) 4 microg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 microg/mL and 4 microg/mL, 80.9% and 93.1% of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.
authors.affiliation: Division of Infectious Diseases, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taoyuan, Taiwan.
authors.forename: Jien-Wei
authors.initials: JW
authors.lastname: Liu
authors.forename: Lih-Shinn
authors.initials: LS
authors.lastname: Wang
authors.forename: Yu-Jen
authors.initials: YJ
authors.lastname: Cheng
authors.forename: Gwo-Jong
authors.initials: GJ
authors.lastname: Hsu
authors.forename: Po-Liang
authors.initials: PL
authors.lastname: Lu
authors.forename: Yung-Ching
authors.initials: YC
authors.lastname: Liu
authors.forename: Chih-Ming
authors.initials: CM
authors.lastname: Chen
authors.forename: Chun-Ming
authors.initials: CM
authors.lastname: Lee
authors.forename: Wu
authors.initials: W
authors.lastname: Sun
authors.forename: Tsrang-Neng
authors.initials: TN
authors.lastname: Jang
authors.forename: Ping-Cherng
authors.initials: PC
authors.lastname: Chiang
authors.forename: Yin-Ching
authors.initials: YC
authors.lastname: Chuang
authors.forename: Hsiu-Chen
authors.initials: HC
authors.lastname: Lin
authors.forename: Zhi-Yuan
authors.initials: ZY
authors.lastname: Shi
authors.forename: Hsiang-Chi
authors.initials: HC
authors.lastname: Kung
authors.forename: Cheng-Hua
authors.initials: CH
authors.lastname: Huang
authors.forename: Shih-Ming
authors.initials: SM
authors.lastname: Tsao
authors.forename: Chin-Te
authors.initials: CT
authors.lastname: Lu
authors.forename: Chun-Hsing
authors.initials: CH
authors.lastname: Liao
authors.forename: Po-Ren
authors.initials: PR
authors.lastname: Hsueh
mesh_terms: D000151:Acinetobacter Infections / Q000382:microbiology*; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000302:isolation & purification*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013624:Taiwan; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline